Eisai Receives Approval for a New Oral Jelly Formulation of Aricept for the Treatment of Alzheimer’s Disease in Japan
24-Jul-2009
- Japan
Aricept® is an acetylcholinesterase inhibitor developed by Eisai, which works to increase levels of acetylcholine, a neurotransmitter, in the brain. It is the only approved treatment for Alzheimer’s disease in Japan, and is used in the treatment of patients with mild to severe forms of the disease.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.